Durable treatment options that ensure consistent treatment outcomes and reduce the burden of multiple injections are an unmet need for neovascular age-related macular degeneration and other retinal vascular diseases treated with anti-VEGFs.
Looking at a large database of 98,821 eyes, the SIERRA-AMD real-world evidence study confirmed what other similar studies found previously: The treatment burden leads to missed visits and decreased injection frequency, with consequent gradual decline in visual acuity over time.
“The biggest unmet need in patients with neovascular age-related macular
Uncategorized